Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 61.1% in December

Aligos Therapeutics, Inc. (NASDAQ:ALGS) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 457,100 shares, a growth of 61.1% from the November 30th total of 283,800 shares. Approximately 17.1% of the company’s shares are short sold. Based on an average daily trading volume, of 350,200 shares, the short-interest ratio is presently 1.3 days.

Aligos Therapeutics Stock Down 5.1 %

Shares of NASDAQ ALGS traded down $2.22 during midday trading on Friday, hitting $41.15. The stock had a trading volume of 462,504 shares, compared to its average volume of 116,735. The company has a fifty day moving average price of $22.23 and a 200 day moving average price of $15.24. The company has a market capitalization of $147.65 million, a price-to-earnings ratio of -3.09 and a beta of 2.73. Aligos Therapeutics has a 1-year low of $6.76 and a 1-year high of $44.39.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($3.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.15) by ($0.92). Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. The business had revenue of $1.27 million for the quarter, compared to analysts’ expectations of $1.00 million. During the same quarter in the prior year, the firm earned ($10.25) earnings per share. On average, research analysts forecast that Aligos Therapeutics will post -10.36 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 target price on shares of Aligos Therapeutics in a research report on Thursday, November 7th.

Institutional Trading of Aligos Therapeutics

An institutional investor recently raised its position in Aligos Therapeutics stock. Acadian Asset Management LLC increased its stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS) by 26.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 829,485 shares of the company’s stock after buying an additional 171,490 shares during the quarter. Acadian Asset Management LLC owned about 1.06% of Aligos Therapeutics worth $289,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).